Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 17/20 | 0.54 |
| ▸ | PLA2G10 | O15496 | 4/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 4/20 | 0.43 |
| ▸ | PLA2G2E | Q9NZK7 | 4/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.43 |
| ▸ | PLA2G2F | Q9BZM2 | 2/20 | 0.42 |
| ▸ | PLA2G2D | Q9UNK4 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.42 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.42 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818181 | 0.92 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL29862616 | 0.92 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL6693386 | 0.91 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL6693400 | 0.91 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL6690205 | 0.89 | PLA2G2A (0.58) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL6695139 | 0.88 | PLA2G2A (0.51) | PLA2G2APLA2G10 | |
| SCHEMBL3258181 | 0.88 | NPC1 (0.48) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL6692869 | 0.87 | PLA2G2A (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL818659 | 0.85 | PLA2G2A (0.43) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL818332 | 0.84 | PLA2G2A (0.41) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0839806-B1 | Substituted tricyclics | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |